2014 Lipoprotein Metabolism Gordon Research Conference and Gordon Research Semina

描述（由申请人提供）： 我们请求部分支持2014年脂蛋白代谢戈登研究会议（GRC）和戈登研究研讨会（GRS）将于2014年6月16日至20日在沃特维尔山谷度假村举行。共同主席小罗伯特·法雷泽博士和Joachim Herz，与过去的主席，2016年副主席和该领域的领导人协商，为GRC计划了九次口头会议：第一节脂肪酶第二节肝脏和肠道脂质代谢第三节高密度脂蛋白和胆固醇逆向转运第四节脂蛋白受体和血管壁第五节中枢神经系统和脂质第6节细胞内脂质代谢第7节脂质和脂蛋白代谢的摘要和主题演讲第8节脂质和脂蛋白代谢的遗传学第9节脂质和心血管疾病的治疗代谢GRS，研究生和博士后研究员介绍和讨论前沿研究的国际论坛。我们的会议满足了NHLBI使命的各个方面。首先，我们汇集了脂蛋白代谢方面的国际领导者，脂蛋白代谢是一个生理过程，占全球心血管风险负担的30%以上。第二，遗传学，生物学，生物化学和脂蛋白的临床表现的性别相关问题已经确定，所以我们的会议满足NHLBI的责任，解决这些问题的妇女。此外，三名讨论领导人是妇女，两名领导人来自欧洲，一名来自加拿大。海伦·霍布斯博士，一位国际公认的人类遗传学家，将是一个主旨发言人。第三，我们的会议经过精心协调，包括与血脂异常和心血管疾病的原因，预防，诊断和治疗有关的各种研究。第四，NHLBI传统上支持我们的会议，我们很荣幸地邀请NHLBI行政部门的选定成员参加。第五，我们同意NHLBI对预防的优先考虑;事实上，目前广泛常规临床使用的心血管疾病一级和二级预防的关键方面（例如他汀类药物）首次在我们过去的会议上报告。第六，共同主席高度重视个人在培训和职业发展初期的参与。

DESCRIPTION (provided by applicant): We request partial support for the 2014 Lipoprotein Metabolism Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) to be held at Waterville Valley Resort, NH on June 16-20, 2014. The Co- Chairs, Drs. Robert Farese, Jr. and Joachim Herz, in consultation with past chairs, the 2016 vice chairs, and leaders in the field, have planned nine oral sessions for the GRC: Session 1 Lipases Session 2 Hepatic & Intestinal Lipid Metabolism Session 3 HDL & Reverse Cholesterol Transport Session 4 Lipoprotein Receptors and Vascular Wall Session 5 CNS & Lipids Session 6 Intracellular Lipid Metabolism Session 7 SHORT TALKS FROM ABSTRACTS AND Keynote Talk on Lipid and Lipoprotein Metabolism Session 8 Genetics of Lipid and Lipoprotein Metabolism Session 9 Therapeutics of Lipid and Cardiovascular Disease The GRC will be preceded by the Lipoprotein Metabolism GRS, an international forum for the presentation and discussion of frontier research by graduate students and postdoctoral fellows. Our conference satisfies all aspects of the NHLBI Mission. First, we bring together international leaders in lipoprotein metabolism, a physiological process that accounts for more than 30% of global cardiovascular risk burden. Second, gender-related issues of genetics, biology, biochemistry, and clinical manifestations of lipoproteins have been identified, so our conference satisfies the NHLBI responsibility for addressing these issues in women. Also, three Discussion Leaders are women, and two leaders are from Europe originally and one from Canada. Dr. Helen Hobbs, an internationally recognized human geneticist, will be a keynote speaker. Third, our conference has been carefully coordinated to include a diversity of research that is related to the causes, prevention, diagnosis and treatment of dyslipidemias and cardiovascular disease. Fourth, the NHLBI has traditionally supported our meeting and we have been honored to invite selected members of NHLBI administration as attendees. Fifth, we share the NHLBI's priority on prevention; indeed key aspects of primary and secondary prevention of cardiovascular disease that are currently in widespread routine clinical use (e.g. statin drugs) were first reported at our past meetings. Sixth, the co-Chairs have placed the highest priority on participation by individuals early in their training and early in their career development.